The CFO's first open-market purchase since joining and the 10% owner's material buy suggest insiders see value after the post-offering stock price. Monitor next quarter's revenue trajectory and ABCL635 Phase 3 initiation for confirmation of the growth narrative.
Drug in focus
ABCL drug pipeline →ABCL635
● Neutral Named in this insider cluster- Impact
- Phase
- Phase 2
- Time to market
- Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
- Next catalyst
- None dated
What to watchThe next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $11.49entry
- T+1 · 18h ago −3.22%α −1.31% · $11.12
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at AbCellera, including the CFO and a 10% owner, made open-market purchases totaling $796K in the week following Q3 earnings that showed 19% revenue growth and a narrower net loss. The CFO's $97K buy and the 10% owner's $699K buy, both outside 10b5-1 plans, signal insider confidence after positive Phase 2 data and a completed $200M equity offering.
Key Financial Metrics
Key Facts
- CFO Andrew Booth purchased 8,600 shares at $11.33 for $97K on 2026-11-13 (no 10b5-1 plan)
- 10% owner Thermopylae Holdings purchased 60,565 shares at $11.54 for $699K on 2026-11-12 (no 10b5-1 plan)
- Total open-market purchases: $796K
- Q3 2026 revenue $10.6M (+19% YoY), net loss narrowed to $40.8M from $57.1M
- Positive Phase 2 data for ABCL635 in menopausal hot flashes announced
- Company completed a $200M equity offering and held >$890M in liquidity
Financial Impact
Insider purchases total $796K, representing approximately 0.24% of market cap (estimated from $11.54 price and 292M shares outstanding from prior filings)
Risk Factors
- Company remains unprofitable with a $40.8M quarterly net loss
- Recent $200M equity offering diluted existing shareholders
- Insider purchases are small relative to market cap (0.24%) and may not predict near-term stock performance
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ABCL-1794845733049 |
Track record
16 reports on ABCL
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +127.09% at T+20 after the Jul 29, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $11.63 Now $11.12 −4.39% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Bullish 4/10 Viewing Entry $11.49 Now $11.12 −3.22% settles Feb 11
- Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $12.46 Now $11.12 −10.75% settles Feb 8
- Aug 24, 202612w ago Insider Cluster Mixed 5/10 Entry $12.50 Now $11.12 −11.04% settles Nov 18
- Aug 18, 202612w ago Insider Cluster Bullish 5/10 Entry $11.12 to $11.95 Now $11.12 −0.00% ▲ +7.46% +8.46% vs SPY
- Aug 15, 202613w ago Institutional Cluster Bearish 6/10 Entry $11.20 to $12.46 Now $11.12 +0.71% ▼ −11.25% −14.19% vs SPY
- Aug 11, 202613w ago 424B5 Bearish 7/10 Entry $10.36 to $11.13 Now $11.12 −7.39% ▼ −7.48% −12.60% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Entry $9.34 to $12.18 Now $11.12 +19.06% ▲ +30.41% +32.82% vs SPY
- Jul 29, 202615w ago 8-K Bullish 6/10 Entry $5.39 to $11.37 Now $11.12 +106.31% ▲ +110.95% +106.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers